Mechanisms of disulfiram-induced cocaine abstinence: Antabuse and cocaine relapse

Molecular Interventions

Volumn 9, Issue 4, 2009, Pages 175-187

  Gaval Cruz, Meriem ^a   Weinshenker, David ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMPHETAMINE; BUPRENORPHINE; CATECHOLAMINE; COCAINE; DISULFIRAM; DOPAMINE BETA MONOOXYGENASE; GLUTAMIC ACID; METHADONE; NALTREXONE; NORADRENALIN; OPIATE; PLACEBO;

ALCOHOL METABOLISM; ALCOHOLISM; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITIVE THERAPY; DOPAMINE METABOLISM; DOPAMINE RELEASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MECHANISM; DRUG WITHDRAWAL; FATIGUE; FLUSHING; HUMAN; HYPOTENSION; LIVER TOXICITY; NAUSEA; NEUROTRANSMISSION; NONHUMAN; PARANOIA; REVIEW; SIDE EFFECT; SWEATING; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING; WEAKNESS;

ANIMALS; CLINICAL TRIALS AS TOPIC; COCAINE-RELATED DISORDERS; DISULFIRAM; DOPAMINE BETA-HYDROXYLASE; ENZYME INHIBITORS; HUMANS; RECURRENCE;

EID: 69749094506     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.9.4.6     Document Type: Review

References (159)

1. Kitson, T.M. The disulfiram-ethanol reaction. J. Stud. Alcohol. 38, 96-113 (1977).
2. George, T.P., Chawarski, M.C., Pakes, J., Carroll, K.M., Kosten, T.R., and Schottenfeld, R.S. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: A preliminary trial. Biol. Psychiatry 47, 1080-1086 (2000). (Pubitemid 30336217)
3. Petrakis, I.L., Carroll, K.M., Nich, C., Gordon, L.T., McCance-Katz, E.F., Frankforter, T., and Rounsaville, B.J. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 95, 219-228 (2000). (Pubitemid 30111242)
4. Carroll, K.M., Fenton, L.R., Ball, S.A., Nich, C., Frankforter, T.L., Shi, J., and Rounsaville, B.J. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: A randomized placebo-controlled trial. Arch. Gen. Psychiatry 61, 264-272 (2004). This paper reports the first systematic study of the effect of disulfiram on cocaine use in a general population of cocaine users, regardless of concurrent ethanol intake. It put forth the notion that disulfiram's mechanism of action in curbing cocaine intake must be independent of its effects on alcohol metabolism.
5. Levin, E.Y., Levenberg, B., and Kaufman, S. The enzymatic conversion of 3,4-dihydroxyphenylethylamine to norepinephrine. J. Biol. Chem. 235, 2080-2086 (1960).
6. Deitrich, R.A. and Erwin, V.G. Mechanism of the inhibition of aldehyde dehydrogenase in vivo by disulfiram and diethyldithiocarbamate. Mol. Pharmacol. 7, 301-307 (1971).
7. Johansson, B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr. Scand. Suppl. 369, 15-26 (1992).
8. Hald, J. and Jacobsen, E. A drug sensitizing the organism to ethyl alcohol. Lancet 2, 1001-1004 (1948).
9. Johnston, C.D. The in vitro reaction between tetraethylthiuram disulfide (antabuse) and glutathione. Arch Biochem. Biophys. 44, 249-251 (1953).
10. Torronen, R. and Marselos, M. Changes in the hepatic copper conent after treatment with foreign compounds. Arch. Toxicol. Suppl. 247-249 (1978).
11. Suh, J.J., Pettinati, H.M., Kampman, K.M., and O'Brien, C.P. The status of disulfiram: A half of a century later. J. Clin. Psychopharmacol. 26, 290-302 (2006). This paper provides a thorough summary of recent supervised clinical trials testing disulfiram in the treatment of alcoholics.
12. Chick, J., Gough, K., Falkowski, W., Kershaw, P., Hore, B., Mehta, B., Ritson, B., Ropner, R., and Torley, D. Disulfiram treatment of alcoholism. Br. J. Psychiatry. 161, 84-89 (1992).
13. Gerrein, J.R., Rosenberg, C.M., and Manohar, V. Disulfiram maintenance in outpatient treatment of alcoholism. Arch. Gen. Psychiatry 28, 798-802 (1973).
14. Azrin, N.H. Improvements in the community-reinforcement approach to alcoholism. Behav. Res. Ther. 14, 339-348 (1976).
15. Keane, T.M., Foy, D.W., Nunn, B., and Rychtarik, R.G. Spouse contracting to increase antabuse compliance in alcoholic veterans. J. Clin. Psychol. 40, 340-344 (1984).
16. Robichaud, C., Strickler, D., Bigelow, G., and Liebson, I. Disulfiram maintenance employee alcoholism treatment: A three-phase evaluation. Behav. Res. Ther. 17, 618-621 (1979).
17. Sereny, G., Sharma, V., Holt, J., and Gordis, E. Mandatory supervised antabuse therapy in an outpatient alcoholism program: A pilot study. Alcohol. Clin. Exp. Res. 10, 290-292 (1986).
18. Brewer, C. Patterns of compliance and evasion in treatment programmes which include supervised disulfiram. Alcohol Alcohol. 21, 385-388 (1986). (Pubitemid 17228581)
19. Besson, J., Aeby, F., Kasas, A., Lehert, P., and Potgieter, A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: A controlled study. Alcohol. Clin. Exp. Res. 22, 573-579 (1998).
20. Frisoni, G.B. and Di Monda, V. Disulfiram neuropathy. (1971-1988) and report of a case. Alcohol Alcohol. 24, 429-437 (1989).
21. Kristenson, H. How to get the best out of antabuse. Alcohol Alcohol. 30, 775-783 (1995). (Pubitemid 26017478)
22. Wilson, H. Side effects of disulfiram. Br Med J. 2, 1610-1611 (1962).
23. Dupuy, O., Flocard, F., Vial, C., Rode, G., Charles, N., Boisson, D., and Flechaire, A. Disulfiram (Esperal) toxicity. Apropos of 3 original cases. Rev. Med. Interne. 16, 67-72 (1995).
24. Closser, M.H. and Kosten, T.R. Alcohol and cocaine abuse. A comparison of epidemiology and clinical characteristics. Recent Dev. Alcohol. 10, 115-128 (1992).
25. Grant, B.F. and Harford, T.C. Concurrent and simultaneous use of alcohol with cocaine: Results of national survey. Drug. Alcohol. Depend. 25, 97-104 (1990).
26. Weiss, R.D., Mirin, S.M., Griffin, M.L., and Michael, J.L. Psychopathology in cocaine abusers. Changing trends. J. Nerv. Ment. Dis. 176, 719-725 (1988).
27. Khalsa, H., Paredes, A., and Anglin, M.D. The role of alcohol in cocaine dependence. Recent Dev. Alcohol. 10, 7-35 (1992).
28. Dean, R.A., Christian, C.D., Sample, R.H., and Bosron, W.F. Human liver cocaine esterases: Ethanol-mediated formation of ethylcocaine. FASEB J. 5, 2735-2739 (1991).
29. Perez-Reyes, M. and Jeffcoat, A.R. Ethanol/cocaine interaction: Cocaine and cocaethylene plasma concentrations and their relationship to subjective and cardiovascular effects. Life Sci. 51, 553-563 (1992).
30. McCance-Katz, E.F., Price, L.H., McDougle, C.J., Kosten, T.R., Black, J.E., and Jatlow, P.I. Concurrent cocaine-ethanol ingestion in humans: Pharmacology, physiology, behavior, and the role of cocaethylene. Psychopharmacology (Berl). 111, 39-46 (1993).
31. Rose, J.S. Cocaethylene: A current understanding of the active metabolite of cocaine and ethanol. Am. J. Emerg. Med. 12, 489-490 (1994).
32. Farre, M., de la Torre, R., Gonzalez, M.L., Teran, M.T., Roset, P.N., Menoyo, E., and Cami, J. Cocaine and alcohol interactions in humans: Neuroendocrine effects and cocaethylene metabolism. J. Pharmacol. Exp. Ther. 283, 164-176 (1997).
33. Jatlow, P., Hearn, W.L., Elsworth, J.D., Roth, R.H., Bradberry, C.W., and Taylor, J.R. Cocaethylene inhibits uptake of dopamine and can reach high plasma concentrations following combined cocaine and ethanol use. NIDA Res. Monogr. 105, 572-573 (1990).
34. Hearn, W.L., Flynn, D.D., Hime, G.W., Rose, S., Cofino, J.C., Mantero-Atienza, E., Wetli, C.V., and Mash, D.C. Cocaethylene: A unique cocaine metabolite displays high affinity for the dopamine transporter. J. Neurochem. 56, 698-701 (1991).
35. Jatlow, P., Elsworth, J.D., Bradberry, C.W., Winger, G., Taylor, J.R., Russell, R., and Roth, R.H. Cocaethylene: A neuropharmacologically active metabolite associated with concurrent cocaine-ethanol ingestion. Life Sci. 48, 1787-1794 (1991).
36. Bunney, E.B., Appel, S.B. and Brodie, M.S. Electrophysiological effects of cocaethylene, cocaine, and ethanol on dopaminergic neurons of the ventral tegmental area. J. Pharmacol. Exp. Ther. 297, 696-703 (2001).
37. Hart, C.L., Jatlow, P., Sevarino, K.A., and McCance-Katz, E.F. Comparison of intravenous cocaethylene and cocaine in humans. Psychopharmacology (Berl). 149, 153-162 (2000). (Pubitemid 30238953)
38. Raven, M.A., Necessary, B.D., Danluck, D.A., and Ettenberg, A. Comparison of the reinforcing and anxiogenic effects of intravenous cocaine and cocaethylene. Exp. Clin. Psychopharmacol. 8, 117-124 (2000).
39. Schechter, M.D. and Meehan, S.M. The lethal effects of ethanol and cocaine and their combination in mice: implications for cocaethylene formation. Pharmacol. Biochem. Behav. 52, 245-248 (1995).
40. Higgins, S.T., Budney, A.J., Bickel, W.K., Hughes, J.R., and Foerg, F. Disulfiram therapy in patients abusing cocaine and alcohol. Am. J. Psychiatry. 150, 675-676 (1993). This was the first published study to show disulfiram therapy significantly decreased both cocaine and alcohol use in comorbid abusers. It laid the foundation for future studies to examine the direct contribution of disulfiram to each of these outcomes.
41. Carroll, K., Ziedonis, D., O'Malley, S., McCance-Katez, E., Gordon, L., and Rounsaville, B. Pharmacologic interventions for alcohol-and-cocaine-abusing individuals. Am. J. Addictions 2, 77-79 (1993).
42. Carroll, K.M., Nich, C., Ball, S.A., McCance, E., and Rounsavile, B.J. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 93, 713-727 (1998). (Pubitemid 28230603)
43. Carroll, K.M., Nich, C., Ball, S.A., McCance, E., Frankforter, T.L., and Rounsaville, B.J. One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: Sustained effects of treatment. Addiction 95, 1335-1349 (2000). This paper is the follow-up report to a clinical trial testing disulfiram on cocaine and alcohol users. It was the first to show that disulfiram treatment promotes cocaine abstinence and the effect is sustained for at least one year. (Pubitemid 30707678)
44. Grassi, M.C., Cioce, A.M., Giudici, F.D., Antonilli, and L., Nencini, P. Short-term efficacy of disulfiram or naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: A pilot study. Pharmacol. Res. 55, 117-121 (2007).
45. Pettinati, H.M., Kampman, K.M., Lynch, K.G., Xie, H., Dackis, C., Rabinowitz, A.R., and O'Brien, C.P. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict. Behav. 33, 651-667 (2008).
46. Nich, C., McCance-Katz, E.F., Petrakis, I.L., Cubells, J.F., Rounsaville, B.J., and Carroll, K.M. Sex differences in cocaine-dependent individuals' response to disulfiram treatment. Addict. Behav. 29, 1123-1128 (2004).
47. McCance-Katz, E.F., Kosten, T.R., and Jatlow, P. Disulfiram effects on acute cocaine administration. Drug Alcohol Depend. 52, 27-39 (1998). (Pubitemid 28448699)
48. McCance-Katz, E.F., Kosten, T.R., and Jatlow, P. Chronic disulfiram treatment effects on intranasal cocaine administration: Initial results. Biol. Psychiatry 43, 540-543 (1998). (Pubitemid 28161300)
49. Hameedi, F.A., Rosen, M.I., McCance-Katz, E.F., McMahon, T.J., Price, L.H., Jatlow, P.I., Woods, S.W., and Kosten, T.R. Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans. Biol. Psychiatry 37, 560-563 (1995).
50. Mutschler, J., Diehl, A., and Kiefer, F. Pronounced paranoia as a result of cocaine-disulfiram interaction: Case report and mode of action. J. Clin. Psychopharmacol. 29, 99-101 (2009).
51. Murthy, K.K. Psychosis during disulfiram therapy for alcoholism. J. Indian. Med. Assoc. 95, 80-81 (1997).
52. Ceylan, M.E., Turkcan, A., Mutlu, E., and Onal, O. Manic episode with psychotic symptoms associated with high dose of disulfiram: A case report. J. Clin. Psychopharmacol. 27, 224-225 (2007).
53. Baker, J.R., Jatlow, P., and McCance-Katz, E.F. Disulfiram effects on responses to intravenous cocaine administration. Drug Alcohol Depend. 87, 202-209 (2007). (Pubitemid 46215924)
54. Sofuoglu, M., Poling, J., Waters, A., Sewell, A., Hill, K., and Kosten, T. Disulfiram enhances subjective effects of dextroamphetamine in humans. Pharmacol. Biochem. Behav. 90, 394-398 (2008).
55. Malcolm, R., Olive, M.F., and Lechner, W. The safety of disulfiram for the treatment of alcohol and cocaine dependence in randomized clinical trials: Guidance for clinical practice. Expert Opin. Drug Saf. 7, 459-472 (2008).
56. Maj, J. and Przegalinski, E. Disulfiram and some effects of amphetamine in mice and rats. J. Pharm. Pharmacol. 19, 341-342 (1967).
57. Maj, J., Przegalinski, E., and Wielosz, M. Disulfiram and the drug-induced effects on motility. J Pharm Pharmacol. 20, 247-248 (1968).
58. Haile, C.N., During, M.J., Jatlow, P.I., Kosten, T.R., and Kosten, T.A. Disulfiram facilitates the development and expression of locomotor sensitization to cocaine in rats. Biol. Psychiatry 54, 915-921 (2003).
59. Gaval-Cruz, M., Schroeder, J.P., Liles, L.C., Javors, M.A., and Weinshenker, D. Effects of disulfiram and dopamine beta-hydroxylase knockout on cocaine-induced seizures. Pharmacol. Biochem. Behav. 89, 556-562 (2008).
60. Wood, P.L. and Altar, C.A. Dopamine release in vivo from nigrostriatal, mesolimbic, and mesocortical neurons: Utility of 3-methoxytyramine measurements. Pharmacol Rev. 40, 163-187 (1988).
61. Burke, W.J., Li, S.W., Williams, E.A., Nonneman, R., and Zahm, D.S. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: Implications for Parkinson's disease pathogenesis. Brain Res. 989, 205-213 (2003).
62. Vaccari, A., Saba, P.L., Ruiu, S., Collu, M., and Devoto, P. Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine. Toxicol. Appl. Pharmacol. 139, 102-108 (1996).
63. Musacchio, J., Kopin, I.J., and Snyder, S. Effects of disulfiram on tissue norepinephrine content and subcellular distribution of dopamine, tyramine and their beta-hydroxylated metabolites. Life Sci. 3, 769-775 (1964).
64. Musacchio, J.M., Goldstein, M., Anagnoste, B., Poch, G., and Kopin, I.J. Inhibition of dopamine-beta-hydroxylase by disulfiram in vivo. J. Pharmacol. Exp. Ther. 152, 56-61 (1966). This was the first demonstration that disulfiram can inhibit dopamine beta-hydroxylase in vivo.
65. Goldstein, M. Inhibition of norepinephrine biosynthesis at the dopamine-beta-hydroxylation stage. Pharmacol. Rev. 18, 77-82 (1966).
66. Goldstein, M. and Nakajima, K. The effects of disulfiram on the repletion of brain catecholamine stores. Life Sci. 5, 1133-1138 (1966).
67. Sesack, S.R., Carr, D.B., Omelchenko, N., and Pinto, A. Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions. Ann. N.Y. Acad. Sci. 1003, 36-52 (2003). This is a comprehensive review of dopamine and glutamate interactions in the cortex, ventral tegmental area, basal ganglia and amygdala. It focuses on tract-tracing and immunocytochemical evidence of reciprocal anatomical connections and common target regions.
68. Gass, J.T. and Olive, M.F. Glutamatergic substrates of drug addiction and alcoholism. Biochem. Pharmacol. 75, 218-265 (2008).
69. Pulvirenti, L. and Diana, M. Drug dependence as a disorder of neural plasticity: Focus on dopamine and glutamate. Rev. Neurosci. 12, 141-158 (2001).
70. Tzschentke, T.M. and Schmidt, W.J. Glutamatergic mechanisms in addiction. Mol. Psychiatry 8, 373-382 (2003).
71. Lapish, C.C., Seamans, J.K., and Chandler, L.J. Glutamate-dopamine cotransmission and reward processing in addiction. Alcohol. Clin. Exp. Res. 30, 1451-1465 (2006).
72. Kotlinska, J. and Biala, G. Memantine and ACPC affect conditioned place preference induced by cocaine in rats. Pol. J. Pharmacol. 52, 179-185 (2000).
73. Maldonado, C., Rodriguez-Arias, M., Castillo, A., Aguilar, M.A., and Minarro, J. Effect of memantine and CNQX in the acquisition, expression and reinstatement of cocaine-induced conditioned place preference. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 932-939 (2007).
74. Pulvirenti, L., Balducci, C., and Koob, G.F. Dextromethorphan reduces intravenous cocaine self-administration in the rat. Eur. J. Pharmacol. 321, 279-283 (1997).
75. Hyytia, P., Backstrom, P., and Liljequist, S. Site-specific NMDA receptor antagonists produce differential effects on cocaine self-administration in rats. Eur. J. Pharmacol. 378, 9-16 (1999).
76. Papp, M., Gruca, P., and Willner, P. Selective blockade of drug-induced place preference conditioning by ACPC, a functional NDMA-receptor antagonist. Neuropsychopharmacology 27, 727-743 (2002). (Pubitemid 35339453)
77. Blokhina, E.A., Kashkin, V.A., Zvartau, E.E., Danysz, W., and Bespalov, A.Y. Effects of nicotinic and NMDA receptor channel blockers on intravenous cocaine and nicotine self-administration in mice. Eur. Neuropsychopharmacol. 15, 219-225 (2005).
78. Backstrom, P. and Hyytia, P. Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology 31, 778-786 (2006).
79. Backstrom, P. and Hyytia, P. Involvement of AMPA/kainate, NMDA, and mGlu5 receptors in the nucleus accumbens core in cue-induced reinstatement of cocaine seeking in rats. Psychopharmacology (Berl). 192, 571-580 (2007).
80. Nagendra, S.N., Faiman, M.D., Davis, K., Wu, J.Y., Newby, X., and Schloss, J.V. Carbamoylation of brain glutamate receptors by a disulfiram metabolite. J. Biol. Chem. 272, 24247-24251 (1997).
81. Mamatha, R.K. and Nagendra, S.N. Effect of disulfiram administration on glutamate uptake by synaptosomes in the rat brain. Eur. J. Pharmacol. 292, 89-94 (1994).
82. Vaccari, A., Ferraro, L., Saba, P., Ruiu, S., Mocci, I., Antonelli, T., and Tanganelli, S. Differential mechanisms in the effects of disulfiram and diethyldithiocarbamate intoxication on striatal release and vesicular transport of glutamate. J. Pharmacol. Exp. Ther. 285, 961-967 (1998).
83. Smith, J.A., Mo, Q., Guo, H., Kunko, P.M., and Robinson, S.E. Cocaine increases extraneuronal levels of aspartate and glutamate in the nucleus accumbens. Brain Res. 683, 264-269 (1995).
84. Meshul, C.K., Noguchi, K., Emre, N., and Ellison, G. Cocaine-induced changes in glutamate and GABA immunolabeling within rat habenula and nucleus accumbens. Synapse 30, 211-220 (1998). (Pubitemid 28376380)
85. Keys, A.S., Mark, G.P., Emre, N., and Meshul, C.K. Reduced glutamate immunolabeling in the nucleus accumbens following extended withdrawal from self-administered cocaine. Synapse 30, 393-401 (1998). (Pubitemid 28506994)
86. Williams, J.M. and Steketee, J.D. Cocaine increases medial prefrontal cortical glutamate overflow in cocaine-sensitized rats: A time course study. Eur. J. Neurosci. 20, 1639-1646 (2004).
87. Kalivas, P.W. Neurobiology of cocaine addiction: Implications for new pharmacotherapy. Am. J. Addict. 16, 71-78 (2007).
88. Faiman, M.D. 1979. Biochemical pharmacology of disulfiram. In: Majchowicz, E., Novel, E.P. (Eds.), Biochemistry and Pharmacology of Ethanol. Plenum, New York, pp. 325-348.
89. Stewart, D.J., Inaba, T., Lucassen, M., and Kalow, W. Cocaine metabolism: Cocaine and norcocaine hydrolysis by liver and serum esterases. Clin. Pharmacol. Ther. 25, 464-468 (1979).
90. Benowitz, N.L. Clinical pharmacology and toxicology of cocaine. Pharmacol. Toxicol. 72, 3-12 (1993).
91. Heikkila, R.E., Orlansky, H., and Cohen, G. Studies on the distinction between uptake inhibition and release of (3H)dopamine in rat brain tissue slices. Biochem. Pharmacol. 24, 847-852 (1975).
92. Reith, M.E., Meisler, B.E., Sershen, H., and Lajtha, A. Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior. Biochem. Pharmacol. 35, 1123-1129 (1986).
93. Ritz, M.C., Lamb, R.J., Goldberg, S.R., and Kuhar, M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237, 1219-1223 (1987).
94. Lake, C.R., Major, L.F., Ziegler, M.G., and Kopin, I.J. Increased sympathetic nervous system activity in alcoholic patients treated with disulfiram. Am. J. Psychiatry 134, 1411-1414 (1977).
95. Frigon, R.P., Converse, J.L., and Stone, R.A. Plasma dopamine betahydroxylase species dependence and in the vitro influence of NEM, copper, and pH. Biochem. Med. 19, 1-15 (1978).
96. Green, A.L. Inhibition of DBH by chelating agents. Biochim. Biophys. Acta. 81(1964).
97. Bourdelat-Parks, B.N., Anderson, G.M., Donaldson, Z.R., Weiss, J.M., Bonsall, R.W., Emery, M.S., Liles, L.C., and Weinshenker, D. Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice. Psychopharmacology (Berl). 183, 72-80 (2005). (Pubitemid 41484184)
98. Grabowski, J., Shearer, J., Merrill, J., and Negus, S.S. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict. Behav. 29, 1439-1464 (2004).
99. Sofuoglu, M. and Kosten, T.R. Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opin. Emerg. Drugs. 11, 91-98 (2006).
100. Weinshenker, D., Schroeder, J.P. There and back again: A tale of norepinephrine and drug addiction. Neuropsychopharmacology. 32, 1433-1451 (2007). This review focuses on the role of norepinephrine in reward, dopamine signaling and drug addiction. It thoroughly summarizes clinical and animal data from an array of behavioral paradigms used to test drug responses.
101. Mejias-Aponte, C.A., Drouin, C. and Aston-Jones, G. Adrenergic and noradrenergic innervation of the midbrain ventral tegmental area and retrorubral field: Prominent inputs from medullary homeostatic centers. J. Neurosci. 29, 3613-3626 (2009).
102. Grenhoff, J., Nisell, M., Ferre, S., Aston-Jones, G., and Svensson, T.H. Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J. Neural Transm. Gen. Sect. 93, 11-25 (1993).
103. Grenhoff, J. and Svensson, T.H. Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. Eur. J. Pharmacol. 233, 79-84 (1993).
104. Lategan, A.J., Marien, M.R., and Colpaert, F.C. Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis. Brain Res. 523, 134-138 (1990).
105. Ventura, R., Cabib, S., Alcaro, A., Orsini, C., and Puglisi-Allegra, S. Norepinephrine in the prefrontal cortex is critical for amphetamineinduced reward and mesoaccumbens dopamine release. J. Neurosci. 23, 1879-1885 (2003).
106. Ventura, R., Morrone, C., and Puglisi-Allegra, S. Prefrontal/accumbal catecholamine system determines motivational salience attribution to both reward- and aversion-related stimuli. Proc. Natl. Acad. Sc.i USA 104, 5181-5186 (2007).
107. Schank, J.R., Ventura, R., Puglisi-Allegra, S., Alcaro, A., Cole, C.D., Liles, L.C., Seeman, P., and Weinshenker, D. Dopamine beta-hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine. Neuropsychopharmacology 31, 2221-2230 (2006). This paper reports neurochemical changes and behavioral responses to cocaine in mice dopamine beta-hydroxylase knockout mice, providing strong evidence for the role of norepinephrine and norepinephrine-dopamine interactions in reward. (Pubitemid 44413199)
108. Weinshenker, D., Ferrucci, M., Busceti, C.L. et al. Genetic or pharmacological blockade of noradrenaline synthesis enhances the neurochemical, behavioral, and neurotoxic effects of methamphetamine. J. Neurochem. 105, 471-483 (2008).
109. Snoddy, A.M. and Tessel, R.E. Prazosin: Effect on psychomotor-stimulant cues and locomotor activity in mice. Eur. J. Pharmacol. 116, 221-228 (1985).
110. Darracq, L., Blanc, G., Glowinski, J., and Tassin, J.P. Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of D-amphetamine. J. Neurosci. 18, 2729-2739 (1998). (Pubitemid 28141818)
111. Drouin, C., Darracq, L., Trovero, F., Blanc, G., Glowinski, J., Cotecchia, S., and Tassin, J.P. Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J. Neurosci. 22, 2873-2884 (2002). (Pubitemid 37465836)
112. Auclair, A., Drouin, C., Cotecchia, S., Glowinski, J., and Tassin, J.P. 5-HT2A and alpha1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants. Eur. J. Neurosci. 20, 3073-3084 (2004).
113. Maldonado, R., Robledo, P., Chover, A.J., Caine, S.B., and Koob, G.F. D1 dopamine receptors in the nucleus accumbens modulate cocaine self-administration in the rat. Pharmacol. Biochem. Behav. 45, 239-242 (1993).
114. McGregor, A. and Roberts, D.C. Dopaminergic antagonism within the nucleus accumbens or the amygdala produces differential effects on intravenous cocaine self-administration under fixed and progressive ratio schedules of reinforcement. Brain Res. 624, 245-252 (1993). (Pubitemid 23281826)
115. Epping-Jordan, M.P., Markou, A., and Koob, G.F. The dopamine D-1 receptor antagonist SCH 23390 injected into the dorsolateral bed nucleus of the stria terminalis decreased cocaine reinforcement in the rat. Brain Res. 784, 105-115 (1998). (Pubitemid 28137854)
116. Ahmed, S.H. and Koob, G.F. Changes in response to a dopamine receptor antagonist in rats with escalating cocaine intake. Psychopharmacology (Berl). 172, 450-454 (2004).
117. Thierry, A.M., Tassin, J.P., Blanc, G., and Glowinski, J. Selective activation of mesocortical dopamine system by stress. Nature 263, 242-244 (1976).
118. Abercrombie, E.D., Keefe, K.A., DiFrischia, D.S., and Zigmond, M.J. Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J. Neurochem. 52, 1655-1658 (1989).
119. Jensen, P.G., Curtis, P.D., Dunn, J.A., Austic, R.E., and Richmond, M.E. Field evaluation of capsaicin as a rodent aversion agent for poultry feed. Pest. Manag. Sci. 59, 1007-1015 (2003).
120. Thomas, S.A., Matsumoto, A.M., and Palmiter, R.D. Noradrenaline is essential for mouse fetal development. Nature 374, 643-646 (1995).
121. Thomas, S.A., Marck, B.T., Palmiter, R.D., and Matsumoto, A.M. Restoration of norepinephrine and reversal of phenotypes in mice lacking dopamine beta-hydroxylase. J. Neurochem. 70, 2468-2476 (1998).
122. Weinshenker, D., Miller, N.S., Blizinsky, K., Laughlin, M.L., and Palmiter, R.D. Mice with chronic norepinephrine deficiency resemble amphetamine-sensitized animals. Proc. Natl. Acad. Sci. USA 99, 13873-13877 (2002).
123. Weinshilboum, R.M., Schorott, H.G., Raymond, F.A., Weidman, W.H., and Elveback, L.R. Inheritance of very low serum dopamine-betahydroxylase activity. Am. J. Hum. Genet. 27, 573-585 (1975).
124. Zabetian, C.P., Anderson, G.M., Buxbaum, S.G. et al. A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: Evidence for a major functional polymorphism at the DBH locus. Am. J. Hum. Genet. 68, 515-522 (2001).
125. Cubells, J.F., Kranzler, H.R., McCance-Katz, E., Anderson, G.M., Malison, R.T., Price, L.H., and Gelernter, J. A haplotype at the DBH locus, associated with low plasma dopamine beta-hydroxylase activity, also associates with cocaine-induced paranoia. Mol. Psychiatry 5, 56-63 (2000). (Pubitemid 30088453)
126. Kalayasiri, R., Sughondhabirom, A., Gueorguieva, R., Coric, V., Lynch, W.J., Lappalainen, J., Gelernter, J., Cubells, J.F., and Malison, R.T. Dopamine beta-hydroxylase gene (DbetaH) -1021C - >T influences self-reported paranoia during cocaine self-administration. Biol. Psychiatry 61, 1310-1313 (2007). (Pubitemid 46726260)
127. Mutschler, J., Diehl, A., and Kiefer, F. Pronounced paranoia as a result of cocaine-disulfiram interaction: Case report and mode of action. J. Clin. Psychopharmacol. 29, 99-101 (2009).
128. Yokel, R.A. and Wise, R.A. Attenuation of intravenous amphetamine reinforcement by central dopamine blockade in rats. Psychopharmacology (Berl). 48, 311-318 (1976).
129. Risner, M. and Jones, B.E. Role of noradrenergic and dopaminergic processes in amphetamine self-administration. Pharmacol. Biochem. Behav. 5, 477-482 (1976).
130. Roberts, D.C., Corcoran, M.E., and Fibiger, H.C. On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine. Pharmacol. Biochem. Behav. 6, 615-620 (1977).
131. Guindalini, C., Laranjeira, R., Collier, D., Messas, G., Vallada, H., and Breen, G. Dopamine-beta hydroxylase polymorphism and cocaine addiction. Behav. Brain Funct. 4, 1 (2008).
132. Schottenfeld, R.S., Chawarski, M.C., George, T.P.A., and Cubells, J.F., 2004. Pharmacogenetics of disulfiram for cocaine treatment: Role of DBH genotype. The 66th Annual CPDD Meeting, San Juan, Puerto Rico.
133. Oliveto, O., Poling, J., and Pruzinsky, R., 2004. Efficacy of disulfiram for cocaine abuse in methadone patients: relevance of dopamine betahydroxylase. The 43rd American College of Neuropsychopharmacology (ACNP) meeting, San Juan, Puerto Rico.
134. Leshner, A.I. Addiction is a brain disease, and it matters. Science 278, 45-47 (1997).
135. Hunt, W.A., Barnett, L.W., and Branch, L.G. Relapse rates in addiction programs. J Clin Psychol. 27, 455-456 (1971).
136. Kalivas, P.W. and Volkow, N.D. The neural basis of addiction: A pathology of motivation and choice. Am. J. Psychiatry 162, 1403-1413 (2005).
137. Sinha, R. and Li, C.S. Imaging stress- and cue-induced drug and alcohol craving: Association with relapse and clinical implications. Drug Alcohol Rev. 26, 25-31 (2007).
138. Drummond, D.C. What does cue-reactivity have to offer clinical research? Addiction 95 Suppl 2, S129-144 (2000).
139. Sinha, R., Garcia, M., Paliwal, P., Kreek, M.J., and Rounsaville, B.J. Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. Arch. Gen. Psychiatry 63, 324-331 (2006).
140. Ikemoto, S. and Wise, R.A. Mapping of chemical trigger zones for reward. Neuropharmacology. 47 Suppl 1, 190-201 (2004). (Pubitemid 39298264)
141. Kelley, A.E., Schiltz, C.A., and Landry, C.F. Neural systems recruited by drug- and food-related cues: studies of gene activation in corticolimbic regions. Physiol. Behav. 86, 11-14 (2005).
142. Panlilio, L.V. and Goldberg, S.R. Self-administration of drugs in animals and humans as a model and an investigative tool. Addiction 102, 1863-1870 (2007). This review summarizes popular drug self-administration paradigms used in animal research, discussing their variations, advantages, limitations and their validity in modeling drug addiction in humans.
143. Davis, W.M., Smith, S.G., and Khalsa, J.H. Noradrenergic role in the self-administration of morphine or amphetamine. Pharmacol. Biochem. Behav. 3, 477-484 (1975).
144. Leri, F., Flores, J., Rodaros, D., and Stewart, J. Blockade of stress-induced but not cocaine-induced reinstatement by infusion of noradrenergic antagonists into the bed nucleus of the stria terminalis or the central nucleus of the amygdala. J. Neurosci. 22, 5713-5718 (2002). This paper conclusively demonstrated that blockade of norepinephrine transmission in stress-related brain circuits attenuates stress-induced reinstatement of drug seeking. (Pubitemid 35386493)
145. Zhang, X.Y. and Kosten, T.A. Prazosin, an alpha-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking. Biol. Psychiatry 57, 1202-1204 (2005).
146. Lee, B., Tiefenbacher, S., Platt, D.M., and Spealman, R.D. Pharmacological blockade of alpha2-adrenoceptors induces reinstatement of cocaine-seeking behavior in squirrel monkeys. Neuropsychopharmacology 29, 686-693 (2004). (Pubitemid 38402476)
147. Platt, D.M., Rowlett, J.K., and Spealman, R.D. Noradrenergic mechanisms in cocaine-induced reinstatement of drug seeking in squirrel monkeys. J. Pharmacol. Exp. Ther. 322, 894-902 (2007).
148. Brown, Z.J., Tribe, E., D'Souza N, A., and Erb, S. Interaction between noradrenaline and corticotrophin-releasing factor in the reinstatement of cocaine seeking in the rat. Psychopharmacology (Berl). 203, 121-130 (2009).
149. Sinha, R., Catapano, D., and O'Malley, S. Stress-induced craving and stress response in cocaine dependent individuals. Psychopharmacology (Berl). 142, 343-351 (1999). (Pubitemid 29187622)
150. Sinha, R., Fuse, T., Aubin, L.R., and O'Malley, S.S. Psychological stress, drug-related cues and cocaine craving. Psychopharmacology (Berl). 152, 140-148 (2000). (Pubitemid 30776406)
151. Brewer, D.D., Catalano, R.F., Haggerty, K., Gainey, R.R., and Fleming, C.B. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction 93, 73-92 (1998). (Pubitemid 28045140)
152. Kosten, T.R., Rounsaville, B.J., and Kleber, H.D. A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts. Arch. Gen. Psychiatry 43, 733-738 (1986).
153. Piazza, P.V. and Le Moal, M.L. Pathophysiological basis of vulnerability to drug abuse: Role of an interaction between stress, glucocorticoids, and dopaminergic neurons. Annu. Rev. Pharmacol. Toxicol. 36, 359-378 (1996).
154. Piazza, P.V. and Le Moal, M. The role of stress in drug self-administration. Trends Pharmacol. Sci. 19, 67-74 (1998).
155. Kreek, M.J. and Koob, G.F. Drug dependence: Stress and dysregulation of brain reward pathways. Drug Alcohol Depend. 51, 23-47 (1998).
156. Heimer, L., Alheid, G.F., and Zahm, D.S., 1993. Basal forebrain organization: An anatomical framework for motor aspects of drive and motivation. In: Kalivas, P.W., Barnes, C.D. (Eds.), Limbic Motor Circuits and Neuropsychiatry. CRC Press, Boca Raton, pp. 1-43.
157. Smith, R.J. and Aston-Jones, G. Noradrenergic transmission in the extended amygdala: role in increased drug-seeking and relapse during protracted drug abstinence. Brain Struct. Funct. 213, 43-61 (2008). This paper gives a detailed analysis of norepinephrine and corticosterone releasing factor interactions in the amygdala and how it mediates behavioral responses to drugs of abuse. It explains how stress response systems affect reward processing during protracted drug abstinence.
158. Rudoy, C.A. and Van Bockstaele, E.J. Betaxolol, a selective beta(1)-adrenergic receptor antagonist, diminishes anxiety-like behavior during early withdrawal from chronic cocaine administration in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 1119-1129 (2007).
159. Schank J.R., Liles, L.C., and Weinshenker, D. Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety. Biol. Psychiatry 63, 1007-1012 (2008).